(RTTNews) - Genentech, a member of the Roche Group (RO.SW: News , RHHBY.PK), announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer. The company said its investigational medicine trastuzumab emtansine showed improvement in Progression-Free Survival compared to Standard of Care.
The study compared trastuzumab emtansine to standard treatment with Herceptin plus docetaxel chemotherapy. The company said the results showed that people who received trastuzumab emtansine experienced a 41 percent reduction in the risk of their disease worsening or death and lived a median of five months longer without their disease worsening.
The company said the results also showed, people who received trastuzumab emtansine experienced fewer common and severe adverse events compared to those who received Herceptin plus chemotherapy, with the rate of Grade 3 or higher adverse events reduced by nearly half.
Trastuzumab emtansine is an investigational medicine known as an ADC that attaches trastuzumab and the chemotherapy DM1 together using a stable linker.
TDM4450g is a Phase II, international, multicenter, two-arm, open-label study that enrolled 137 patients with previously untreated, HER2-positive mBC from 108 sites.
For comments and feedback: contact editorial@rttnews.com
No comments:
Post a Comment